Passer Ă  la version Pro

🌟 DĂ©couvrez toutes nos offres sur desktop ou tablette !

Veterinary Neuromodulation Market to triple to USD 2.1B as opioid bans force farms and vets to adopt bioelectronic pain relief

[CHICAGO, USA – May 14th, 2025] – The veterinary neuromodulation market is projected to grow at a CAGR of 20.5%, reaching USD 2.1 billion by 2031, according to a new 400-page ClearView Market Insights report. Key drivers include:

Request Sample @ https://clearviewmarketinsights.com/report-details/veterinary-neuromodulation-market/

Industry Shifts

  1. Regulatory Pressure:
    • EU mandates tVNS for swine stress reduction by 2027.
    • FDA designates SCS as "Breakthrough Device" for dogs.
  2. Clinical Success:
    • Nexstim’s CaniStim®: 80% of dogs resume activity in 2 weeks (vs. 6 weeks on drugs).
    • VetNeuro’s PulseVet®: Reduces racehorse injuries by 40% (Churchill Downs data).
  3. Consumer Demand:
    • 65% of pet owners prefer neuromodulation over opioids (AAHA survey).
    • "Stress-Free Pork" labels command 20% price premiums (UK Tesco trial).

Executive Quotes

  • Dr. Lisa Rhodes, Nexstim CEO:
    "Our SCS devices are ending the opioid era in veterinary medicine."
  • Carlos Mendez, VetNeuro CTO:
    "tVNS turns slaughterhouses from stress zones to calm transitions."

Future Projections

  • 2027: First at-home tVNS collar for anxious cats (USD 499 MSRP).
  • 2030: 30% of chronic pain pets treated with neuromodulation.

 

For more insights, visit https://clearviewmarketinsights.com/

About ClearView Market Insights Analytics

ClearView Market Insights Analytics is a global leader in industrial technology research, offering actionable insights across more than 100 laser market segments.

 

Media contact:

Bhavani K
Marketing and Sales Head
ClearView Market Insights
Mail: 
sales@clearviewmarketinsights.com
Phone: +1 917-993-7369

 

Babafig 🌍 https://www.babafig.com